TrialNet

Type 1 Diabetes TrialNet logo in blue and red

What is TrialNet

Type 1 Diabetes TrialNet comprises a network of 18 clinical centres throughout the United States, Canada, Finland, United Kingdom, Italy, Australia, and New Zealand and is dedicated to the study, prevention, and early treatment of Type 1 diabetes.

In the UK TrialNet is led from the coordinating centre in Bristol with 11 affiliate sites nationwide, including Aberdeen, with a further 6 new sites currently in set up.

UK Map showing TrialNet Sites

TrialNet is currently conducting 3 types of research:

  • Natural History Study: looking at how type 1 diabetes develops in those individuals identified as being at risk of contracting the disease.
  • Diabetes Prevention Studies: testing therapies that may delay or prevent the onset of type 1 diabetes.
  • Diabetes Intervention Studies: testing therapies to preserve insulin secretion in people recently diagnosed with type 1 diabetes.

Research staff at the Royal Aberdeen Children’s Hospital (RACH) are currently involved in the Natural History Study (TN01)and the Oral Insulin Study (TN07).

Natural History Study (TN01)

TrialNet screens relatives of people with type 1 diabetes as they have about 15 times greater risk for developing the disease than people with no family history.

Type 1 diabetes develops when the body creates proteins called autoantibodies which destroy insulin producing cells in the pancreas.

These autoantibodies can be found in the blood up to 10 years before someone is diagnosed with diabetes and can be detected by a blood test.

Oral Insulin Study (TN07)

A previous study called DPT-1 has suggested that oral insulin might delay or prevent type 1 diabetes in some people found to be at risk. TrialNet is now testing oral insulin (insulin taken by mouth) to see if this is the case in individuals who tested positive in the blood test.

Recruitment

The Natural History Study has now recruited 118,235 people worldwide. Of these, 3427 have continued to monitoring (2.9%).

UK recruitment in April 2013 reached a new high of 152 with Aberdeen recruiting 10 new participants!

324 participants worldwide have now fulfilled the eligibility requirements for entry into the Oral Insulin study, with 4 of those coming from the UK.

Future Studies

There are plans to expand the Natural History study to compare blood collection by venous (obtained by puncturing a vein) and capillary routes (from the heel or fingertip) in Natural History Study participants.

A new prevention study is also being designed which plans to look at using Trichuris suis (whipworm) to normalize the immune system of those with autoimmune disorders.

Contact

For more information about the TrialNet studies being conducted in Aberdeen please email Victoria Thomson at victoriathomson@nhs.net.

What is TrialNet

Type 1 Diabetes TrialNet comprises a network of 18 clinical centres throughout the United States, Canada, Finland, United Kingdom, Italy, Australia, and New Zealand and is dedicated to the study, prevention, and early treatment of Type 1 diabetes. In the UK TrialNet is led from the coordinating centre in Bristol with 11 affiliate sites nationwide, including Aberdeen, with a further 6 new sites currently in set up.

 

TrialNet is currently conducting 3 types of research:

·Natural History Study: looking at how type 1 diabetes develops in those individuals identified as being at risk of contracting the disease.

·Diabetes Prevention Studies: testing therapies that may delay or prevent the onset of type 1 diabetes.

·Diabetes Intervention Studies: testing therapies to preserve insulin secretion in people recently diagnosed with type 1 diabetes.

 

Research staff at the Royal Aberdeen Children’s Hospital (RACH) are currently involved in the Natural History Study (TN01)and the Oral Insulin Study (TN07).

Natural History Study (TN01)

TrialNet screens relatives of people with type 1 diabetes as they have about 15 times greater risk for developing the disease than people with no family history. Type 1 diabetes develops when the body creates proteins called autoantibodies which destroy insulin producing cells in the pancreas. These autoantibodies can be found in the blood up to 10 years before someone is diagnosed with diabetes and can be detected by a blood test.

Oral Insulin Study (TN07)

A previous study called DPT-1 has suggested that oral insulin might delay or prevent type 1 diabetes in some people found to be at risk. TrialNet is now testing oral insulin (insulin taken by mouth) to see if this is the case in individuals who tested positive in the blood test.

Recruitment

The Natural History Study has now recruited 118,235 people worldwide. Of these, 3427 have continued to monitoring (2.9%). UK recruitment in April 2013 reached a new high of 152 with Aberdeen recruiting 10 new participants!

324 participants worldwide have now fulfilled the eligibility requirements for entry into the Oral Insulin study, with 4 of those coming from the UK.

Future Studies

There are plans to expand the Natural History study to compare blood collection by venous (obtained by puncturing a vein) and capillary routes (from the heel or fingertip) in Natural History Study participants.A new prevention study is also being designed which plans to look at using Trichuris suis (whipworm) to normalize the immune system of those with autoimmune disorders.

Contact

For more information about the TrialNet studies being conducted in Aberdeen please email Victoria Thompson at victoriathompson@nhs.net.

What is TrialNet

Type 1 Diabetes TrialNet comprises a network of 18 clinical centres throughout the United States, Canada, Finland, United Kingdom, Italy, Australia, and New Zealand and is dedicated to the study, prevention, and early treatment of Type 1 diabetes. In the UK TrialNet is led from the coordinating centre in Bristol with 11 affiliate sites nationwide, including Aberdeen, with a further 6 new sites currently in set up.

 

TrialNet is currently conducting 3 types of research:

  • Natural History Study: looking at how type 1 diabetes develops in those individuals identified as being at risk of contracting the disease.
  • Diabetes Prevention Studies: testing therapies that may delay or prevent the onset of type 1 diabetes.
  • Diabetes Intervention Studies: testing therapies to preserve insulin secretion in people recently diagnosed with type 1 diabetes.

 

Research staff at the Royal Aberdeen Children’s Hospital (RACH) are currently involved in the Natural History Study (TN01)and the Oral Insulin Study (TN07).

Natural History Study (TN01)

TrialNet screens relatives of people with type 1 diabetes as they have about 15 times greater risk for developing the disease than people with no family history. Type 1 diabetes develops when the body creates proteins called autoantibodies which destroy insulin producing cells in the pancreas. These autoantibodies can be found in the blood up to 10 years before someone is diagnosed with diabetes and can be detected by a blood test.

Oral Insulin Study (TN07)

A previous study called DPT-1 has suggested that oral insulin might delay or prevent type 1 diabetes in some people found to be at risk. TrialNet is now testing oral insulin (insulin taken by mouth) to see if this is the case in individuals who tested positive in the blood test.

Recruitment

The Natural History Study has now recruited 118,235 people worldwide. Of these, 3427 have continued to monitoring (2.9%). UK recruitment in April 2013 reached a new high of 152 with Aberdeen recruiting 10 new participants!

324 participants worldwide have now fulfilled the eligibility requirements for entry into the Oral Insulin study, with 4 of those coming from the UK.

Future Studies

There are plans to expand the Natural History study to compare blood collection by venous (obtained by puncturing a vein) and capillary routes (from the heel or fingertip) in Natural History Study participants. A new prevention study is also being designed which plans to look at using Trichuris suis (whipworm) to normalize the immune system of those with autoimmune disorders.

Contact

For more information about the TrialNet studies being conducted in Aberdeen please email Victoria Thomson at victoriathomson@nhs.net.